Affiliations: [a] Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China | [b] Department of Urology, Jiangmen Central Hospital, Jiangmen, Guangdong 529030, China | [c] Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China
Correspondence:
[*]
Corresponding author: Fufu Zheng, Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan Second Road, Yuexiu District, Guangzhou, Guangdong 510080, China. Tel.: +86 13682217860; Fax: +86 020 87333300; E-mail:[email protected]
Note: [1] Xiaoxu Yuan and Enjing Chen contributed equally to this study.
Abstract: AIM: This study aimed to investigate the methylation status of
EGF-like and two follistatin-like domains 2 (TMEFF2) promoter and its correlation with tumor stage and survival outcome in
renal cell carcinoma (RCC). MATERIALS AND METHODS: Paraffin-embedded specimens from 42 RCC
patients were analyzed for TMEFF2 methylation by methylation-specific polymerase
chain reaction. The distribution of TNM/AJCC stages and survival time were
compared among patients with unmethylated and methylated TMEFF2. RESULTS: There were 25 (59.5%) and 17 (40.5%) cases with
methylated (M group) and unmethylated (M group) TMEFF2, respectively. There were
more early-stage cancer patients in U group than in M group. Kaplan-Meier
survival analysis showed that U group had a better but not significant
survival outcome than M group (P = 0.123). CONCLUSION: These findings showed that TMEFF2 methylation is not rare in
RCC, and methylation may play an important role in the tumorigenesis of
ccRCC.
